Review
Towards Possible Cure of Cancer by Immunotherapy of Minimal Residual Disease Using Intentionally Mismatched Donor Lymphocytes
Shimon Slavin1.
Biotherapy International, Israel
Corresponding author: Shimon Slavin1, Biotherapy International, 14 Weizmann Street, Tel Aviv 64239, Israel, Tel: +972 54 942 5456; Fax: +972 3 516 4397; E-mail: slavinMD@gmail.com
Received: April 27, 2020; Accepted: May 18, 2020; Published: May 21, 2020

Abstract
Immunotherapy is now recognized as the most promising approach for control of cancer cells resistant to available anti-cancer modalities, yet, cure in patients with advanced and resistant disease is nearly never accomplished. Preliminary data summarized in the present mini-review provides support to a new treatment strategy for treatment of patients with hematological malignancies and solid tumors, based on a 2-step approach: first, an attempt to apply a stage of minimal residual disease (MRD) by conventional modalities; next, using optimal immunotherapy preferably at an early stage of the disease during MRD focusing on intentionally mismatched, Alloreactive Targeted Activated Cancer Killer cells (ATACK) following well-tolerated immunosuppressive conditioning. Preliminary clinical investigations confirm that short-term circulation of ATACK, including T cells and natural killer (NK) cells activated with IL-2 prior to and following cell infusion can kill by reverse rejection-like mechanism allogeneic malignant target cells, cancer cells and cancer stem cells alike, resulting in cure. Our working hypothesis supported by pre-clinical and preliminary clinical investigations confirming the feasibility to cure cancer by ATACK, justify prospective randomized clinical trials to investigate the feasibility and efficacy of ATACK against cancer.

Keywords: immunotherapy of cancer, intentionally mismatched donor lymphocytes, immunotherapy of hematological malignancies, immunotherapy of solid tumors, Cell-mediate immunotherapy; allogeneic donor lymphocytes, IL-2 activated killer cells; cure of cancer

Introduction
Cancer continues to be a leading cause of death worldwide. Considering lack of information about the causes of malignant transformation, except when viral agents seem to be involved, the universal dogma for treatment of cancer is based on ‘the more the better’ using available anti-cancer agents, attempting to eradicate the primary tumor by optimal resection, followed by chemotherapy or radiation therapy when indicated, considering additional treatment only as soon as secondary metastases become visible, usually focusing on aggressive chemotherapy as the standard of care. For patients with cancer not expected to respond adequately to conventional treatment, especially for treatment of hematological malignancies, myeloablative chemotherapy followed by rescue with stem cell transplantation may be considered in an attempt to eradicate otherwise resistant malignant cells. Over the years it became apparent that in patients with primary resistant cancer or with metastatic disease, cure is unlikely to be accomplished. Indeed, relapse continues to be the single major obstacle in treatment of hematologic malignancies and many solid tumors as well, even following initial complete remission [1,2]. On the other hand, as the intensity of the regimen used for treatment of cancer or using high dose chemotherapy supported by stem cell transplantation (SCT) is escalated, the risks of procedure-related toxicity and mortality increase and recurrent disease may not be preventable [3]. In addition, increased incidence of late complications in patients treated with repeated courses of chemotherapy that may or may not increase survival are likely to impair the quality of life of long-term survivors and their supporting family. It became apparent that newer modalities must be introduced in order to improve the cure rate of patients with hematological malignancies and solid tumors as well as to improve the quality of life of successfully treated patients. For patients resistant to available chemotherapy, immunotherapy became in recent years an acceptable treatment as it was confirmed that activating patient’s immune system could be effective even against otherwise resistant disease. Unfortunately, in the absence of tumor-specific antigens and the unresponsiveness that develops between the immune system and the rapidly developing cancer cells, immunotherapy based on an attempt to immunize patients against cancer or using anti-cancer vaccines is far from being effective [4]. Clearly, the goal of effective immunotherapy should be based on an attempt to break the existing tolerance of the immune system against cancer cells, or
in other words to induce an ‘autoimmune-like’ response against tumor cells recognized as ‘self’ by patient’s unresponsive/tolerant immune system [5]. To date, effective tumor-associated antibodies, such as anti-CD20 in patients with B cell non-Hodgkin’s lymphoma as well as additional monoclonal antibodies against other cancer-associated antigens (e.g. Her2/nu; EGFR; VEGF to mention just a few) may be effective by induction of antibody-dependent cell-mediated cytotoxicity for control tumor progression in responding patients but these are usually not sufficient for complete eradication of the disease [6].

Considering the fact that cancer cells mutate spontaneously as well as consistently acquire resistance to chemotherapy and other available anti-cancer modalities, especially considering the fact that cancer stem cells are a priori resistant to available anti-cancer agents, new approaches are urgently indicated for treatment of otherwise incurable cancer. At present, despite major progress, and innovative use of checkpoint inhibitors, with few exceptions, cancer remains incurable disease. Therefore, newer strategies are needed in an attempt to control malignant cells resistant to chemotherapy.

As will be suggested in this short article, cell-mediated immunotherapy by alloreactive lymphocytes that can be targeted against cancer cells at the stage of minimal residual disease (MRD) which can be consistently accomplished in a large majority of patients at an early stage of the disease may represent one of the most promising approaches for cure of cancer. Aiming for cure, application of any effective anti-cancer modality focusing on immunotherapy provides the optimal, sometimes the only, opportunity for cure.

Considering the fact that there are no two cancers that are exactly the same and no two patients that are exactly the same, treatment of cancer should be fully personalized, both cancer-specific and patient-specific. As will be documented here with, cell-mediated immunotherapy by alloreactive, preferably haploidentical, donor lymphocytes may represent one of the most promising approaches to accomplish cure when applied at the stage of minimal residual disease, certainly in patients with hematological malignancies.

The Role of Immunotherapy by Alloreactive Lymphocytes

Following successful animal experiments, the clinical role of allogeneic lymphocytes was introduced in patients with leukemia successfully treated by allogeneic SCT. The role of allogeneic SCT, explored originally by Thomas and colleagues in the early 1970s became the treatment of choice for patients resistant to conventional doses of chemotherapy, and subsequently for patients at high-risk to relapse following maximally tolerated doses of conventional chemotherapy [7]. Subsequently, SCT was successfully utilized for the treatment of genetic diseases and other life-threatening non-malignant indications using the same therapeutic principles for replacement of abnormal host hematopoietic cells with donor hematopoietic cells.

Traditionally, it was considered that high-dose chemoradiotherapy was the main component in the bone marrow transplant procedure and that transplantation of genotypically or phenotypically matched stem cells was mainly indicated for rescue of the lethally treated recipient. Hence, much attention was given to maximize tumor cell kill by maximally tolerated doses of chemotherapy (single agents and combinations of non-cross-reactive agents).

However, it was recognized for many years that the incidence of relapse was high among recipients rescued with autologous or even syngeneic grafts as compared with recipients of allogeneic stem cells. The documented correlation between one of the most serious complications of allogeneic SCT, graft-versus-host disease (GVHD) and successful eradication of all malignant cells, suggest that immune-mediated graft-versus-leukemia (GVL) effects played a major role in elimination of residual tumor cells escaping chemoradiotherapy [8-11].

The possibility that allogeneic lymphocytes administered in the course of SCT eliminate leukemia through immune-mediated GVL effects has been suggested ever since the earliest days of experimental [12-19] and clinical SCT [8-11]. Convincing direct correlation between acute and chronic GVHD and reduced rate of relapse of leukemia in clinical practice was first reported by Weiden et al. [8,9].

Similarly, in analogy to GVL effects, graft-versus-tumor (GVT) effects were also described in a murine model of spontaneous sarcoma [20] and more recently in metastatic breast cancer as well [21,22], as well as in preliminary trials in man [23-25]. The role of immune-mediated GVL effects in the course of SCT was further supported by observations suggesting that relapse while patients were on immunosuppressive treatment with preliminary trials in man [23-25].

The role of immune-mediated GVL effects in the course of SCT was further supported by observations suggesting that relapse while patients were on immunosuppressive treatment with cyclosporine A (CSA) was occasionally reversed by discontinuing immunosuppression [26]. Likewise, it has been documented that the incidence of relapse is lower in patients treated with sub-optimal doses of CSA used as prophylaxis against GVHD [27]. Similarly, data in mice inoculated with murine leukemia treated by SCT indicated that GVL effects mediated by mismatched donor’s bone marrow cells were totally abrogated by concomitant administration of CSA for 10 days [28].

All of the above suggest that allogeneic SCT provided immunocompetent allogeneic donor T lymphocytes, which could react against residual tumor cells of host origin. Hence, the advantage of SCT over conventional chemotherapy lies in the combined effects of the myeloablative dose of chemoradiotherapy given pre-transplantation and the ability of immunocompetent allogeneic donor T lymphocytes to eliminate residual tumor cells of host origin, giving rise to GVL and GVT effects or in fact graft versus any undesirable hematopoietic cells of host origin, including genetically abnormal stem cells or their progeny [29-32].

Interestingly, similarly to the data first reported in mice [14-18], GVL effects occasionally independently of GVHD were also confirmed in clinical practice either following SCT [11] or following donor lymphocyte infusion (DLI) administered post-transplantation to induce GVL effects to treat or prevent relapse when patients are off any post-transplant immunosuppressive agents, as will be detailed below [33-40].

Based on pre-clinical animal models the feasibility of induction of post-transplant GVL or GVT effects induced by alloreactive donor lymphocytes, including both T cells and NK cells present in the allografts, we hypothesized that cell-therapy
The Use of Durable Engraftment of Alloreactive Donor Lymphocytes Following Allogeneic SCT for Immunotherapy of Cancer

Based on the beneficial role of allogeneic stem cell transplantation in comparison with autologous stem cell transplantation and especially transplantation of patients following equal high dose chemotherapy supported by stem cell transplantation obtained from identical twins, we hypothesized that allogeneic lymphocytes of donor origin can be given post grafting for treatment as well as for prevention of relapse in high-risk cases. Indeed, the first successful case where GVL effects were induced by alloreactive DLI in a patient with resistant acute lymphoblastic leukemia (ALL) fully resistant to supra-lethal chemo-radiotherapy, followed by hundreds of patients successfully treated in Israel, subsequently supported by the cumulative international experience in a variety of malignant hematologic diseases that confirmed unequivocally the therapeutic potential of alloreactive lymphocytes [3-40].

The first patient successfully treated by DLI for relapse following SCT was a 30-month-old boy that was referred for SCT at the Hadassah University Hospital in Jerusalem in November 1986 [33-35]. He had been diagnosed as pre-B ALL and relapsed on therapy twice. In December 1986, allogeneic SCT was carried out from a fully matched sister during second resistant relapse. Supra-lethal conditioning included total body irradiation (TBI) 1,200 cGy (two daily fractions of 200 cGy on days -6, -5 and -4) followed by two doses of cyclophosphamide 60 mg/kg (days -3 and -2) and melphalan 60 mg/m2 (day -1). The patient showed no signs of acute GVHD. At one-month post-SCT, the patient presented with full hematologic relapse and several bulky masses confirmed as extramedullary disease, including a progressing retro-tracheal mass necessitating an emergency tracheotomy. He responded to increments of donor (sister) peripheral blood lymphocytes infusions to induce GVL effects. The patient developed grade II GVHD with involvement of the skin and liver. He responded to a short course of corticosteroids and within 2 weeks the palpable masses decreased in size, peripheral blood and bone marrow morphology normalized and cytogenetic analysis confirmed 100% normal female karyotype in all 50 metaphases investigated. To date, more than 30 years following treatment with DLI patient is with no evidence of disease and no residual male cells can be detected by cytogenetic analysis or PCR. The efficacy of DLI for eradication of malignant cells fully resistant to lethal doses of chemo-radiotherapy was confirmed by many centers (36-40) and currently, DLI is considered the treatment of choice for patients relapsing following allogeneic stem cell transplantation [41].

Considering the anti-cancer potential of alloreactive donor lymphocytes, the use of pre-emptive DLI was introduced by our team for prevention of relapse following SCT [42]. The therapeutic role of DLI could be further maximized by in vitro or in vivo activation of alloreactivity of lymphocytes by interleukin-2 [35]. In later years, the well-documented role of alloreactive donor lymphocytes lead to the replacement of myeloablative conditioning for allogeneic SCT with reduced intensity conditioning (RIC) and non-myeloablative stem cell transplantation (NST) [43,44] as documented diagrammatically in Figure 1. Subsequently, the role of reduced intensity conditioning (RIC) was pioneered for the treatment of solid tumors as well, confirming the anti-cancer effects of alloreactive donor lymphocytes also against metastatic solid tumors [45-47].

The Therapeutic Role of Non-Engraftment, Transiently Circulating Intentionally Mismatched, Alloreactive Targeted Activated Cancer Killer Cells (ATACK)

Based on the aforementioned information, we assumed that the therapeutic role of allogeneic lymphocytes could be further maximized using intentionally mismatched, haploidentical or even unrelated donor lymphocytes, and even more effectively by IL-2 activation of lymphocytes, both NK and T cells, prior to and also following cell infusion for rapid and more effective elimination of malignant cells while avoiding the use of prior SCT. The working hypothesis was that effective induction of GVL or GVT could be accomplished by short circulation of non-engrafting lymphocytes following mild immunosuppressive conditioning. The idea was to compensate the short duration of intentionally mismatched lymphocytes in the circulation until rejection by using much more effective GVL- or GVT-inducing lymphocytes. The purpose of the immunosuppressive conditioning was to combine several purposes: (1) reduction of the number and suppression of host lymphocytes to mildly extend the circulation time of donor lymphocytes; (2) establishing a “niche” for newly infused donor-derived killer cells; (3) providing an optimal infra-structure for homeostatic proliferation of alloreactive donor as well as uncommitted newly derived host lymphocytes; (4) suppression of regulatory T cells and other host-derived suppressor cells.

The successful use of intentionally mismatched donor lymphocytes, alloactivated prior to cell infusion and following cell

![Figure 1. Non-myeloablative stem cell transplantation (NST). The rationale for a safer conditioning strategy for allogeneic stem cell transplantation focusing on immunotherapy by durable engraftment of alloreactive donor lymphocytes.

- Maximal conditioning
- Allogeneic stem cells
- Donor lymphocytes
- Tumor elimination attempted by maximizing conditioning prior to transplantation and stem cells indicated for rescue following marrow myeloablation
- Minimal conditioning
- Stem cell transplantation used for tolerance induction and tumor elimination induced by alloreactive donor lymphocytes mostly post transplantation (preferably by graded increments)
infusion by IL-2 using ATACK, was pioneered in a 12 years old patient with AML resistant to myeloablative chemotherapy even following autologous stem cell transplantation in 1992 [48]. Although a stage of MRD was induced by prior autologous stem cell transplantation, residual disease was still documented. Luckily, MRD was successfully eliminated by infusion of haploidentically mismatched maternal lymphocytes activated with IL-2 in vitro for 4 days prior to cell infusion and subsequently following cell infusion too by subcutaneous administration of low dose IL-2 for 5 consecutive days to allow continuous activation of alloreactive donor lymphocytes until their anticipated mandatory rejection [48]. Obviously, consistent rejection of intentionally mismatched lymphocytes prevented any risk of GVHD. Currently, 28 years later, the young girl, now a qualified MD with 2 children, is alive and well with no further treatment, free of any late complications or any signs of chronic GVHD. This patient was the first one to confirm that even transient circulation of alloreactive donor lymphocytes can eliminate malignant cells fully resistant to maximally tolerated doses of myeloablative chemotherapy. Using ATACK following well-tolerated immunosuppressive conditioning, with no prior SCT, anticipated graft-vs-tumor (GVT) effects can be maximized, while preventing any risk of GVHD, simply because mismatched lymphocytes are always rejected spontaneously. It should be noted that intentional engraftment of fully mismatched hematopoietic stem cells is extremely hard to accomplish even following myeloablative conditioning, since rejection of fully matched and even haploidentical hematopoietic stem cells can occur even following maximally tolerated myeloablative conditioning. Rejection of purified haploidentical stem cells, T cell depleted or CD34-enriched, is even harder to be accomplished even following myeloablative conditioning, thus ensuring that durable engraftment of haploidentical or mismatched unrelated lymphocytes that could cause GVHD is unlikely with no prior induction of transplantation tolerance, as was already confirmed by ongoing application of ATACK. Since the successful outcome of our first patient, using ATACK for eradication of chemotherapy resistant disease was also documented in patients with multiple myeloma and non-Hodgkin’s lymphoma, with indications suggesting that similar effects may be also accomplished in patients with metastatic solid tumors, especially if ATACK could be applied at the stage of MRD [41, 45, 49, 50].

Our cumulative experience, which needs to be extended in prospective randomized clinical trials, suggests that at the stage of MRD, cure of patients with hematologic malignancies and possibly also metastatic solid tumors otherwise considered incurable, may benefit or even cured by ATACK [50].

**Immunotherapy of Cancer by Selective Targeting ATACK Against Cancer Associated Antigens by Monoclonal or Bispecific Antibodies**

The selectivity and efficacy of ATACK against cancer can be further improved by targeting intentionally mismatched activated killer cells against malignant cells by monoclonal or bispecific antibodies [51]. Moreover, treatment of minimal residual disease with antibody targeted killer cells may also result in induction of long-lasting anti-cancer immunity, most likely because the Fc portion of the monoclonal or bispecific antibody can bind to antigen presenting cells (dendritic cells or macrophages) leading to processing of cancer antigens and presentation to helper T cells [51, 52].

Immunotherapy of cancer with monoclonal or bispecific antibodies may be an effective way to induce antibody-dependent cell-mediated cytotoxicity which can be accomplished by using commercially available antibodies such as anti-CD20 (Rituximab), anti-Her-2/neu (Herceptin), anti-EGFR (Eribitux), anti-VEGF (Avastin) and bispecific antibodies such as anti-CD3 x anti-EpCAM (Catumaxomab) that were already applied in clinical practice.

Whereas the use of transient circulation of ATACK makes it possible to eliminate truly minimal residual disease. In addition, successful activation of patient’s own immune system during the GVL or GVT induced by ATACK against cancer can sometimes recruit patient’s own T cells to induce long-lasting immunity that can serve as vaccination by memory T cells against residual or re-emerging malignant cells. Indeed, we have already documented the feasibility of cure of cancer in parallel with induction of long-lasting anti-cancer vaccination by targeting ATACK against cancer-associated epithelial cell adhesion molecules (EpCAM) in a pre-clinical animal model by a single treatment that results in elimination of existing cancer cells by alloreactive lymphocytes, followed by induction of host derived memory T cells that can resist a lethal tumor challenge long after rejection of donor lymphocytes and after elimination of the bispecific antibody [52].

**Other Supportive Methods in Preparation for Optimal Treatment of Resistant Residual Disease in Patients with Cancer**

Methods to stimulate patients’ own immune system against cancer include non-specific activation of T cells and NK cells with IL-2 and especially by combining treatment with IL-2 and alpha interferon. The use of interferon may amplify the anti-cancer effects of IL-2 by exposing cell surface MHC and possibly additional cancer-associated antigens on the cell surface of cancer cells. In addition, alpha interferon may also increase the number and enhance the function of NK cells activated by IL-2. Interferon enhances cytokine secretion and degranulation of NK cells and as such increases the cytotoxic potential of NK cells that are also activated by IL-2. We have previously documented that such treatment may be effective for treatment of leukemia/lymphoma in pre-clinical animal experiments [5, 53] and in pilot clinical trials [54,55]. Treatment with IL-2 and alpha interferon significantly improved the disease-free survival and overall survival of patients with Hodgkin’s and non-Hodgkin’s lymphoma treated with high dose chemotherapy and autologous stem cell transplantation prior to cytokine treatment [56,57]. The anti-cancer effects of interferon alpha may also be enhanced by activation of M1 macrophages [58]. In addition, activation of macrophages can also enhance their function as antigen presenting cells [59].

There seems to be no question that additional approaches may be also be used for synergistic activation of patient’s own immune system against cancer, such as Coley’s toxin and oncolytic viruses may prove effective as alternative strategies for breaking the unresponsiveness that exist between patient’s T cells and cancer. In parallel, induction of anti-cancer effects may
be accomplished by successful intra-tumor vaccination using an existing tumor as an internal vaccine [60] future anti-cancer vaccination using metronomic treatment against negative regulators of the immune system such as regulatory T cells [61], checkpoint inhibitors (e.g. CTLA-4 and PD-1/PDL-1) [62,63], myeloid-derived suppressor cells [64], mesenchymal stromal cells (MSC) [65]. These negative regulators can block development of anti-cancer immunity by systemic effects or at the level of the protective tumor microenvironment.

Control of cancer cells by cancer-specific low molecular weight compounds such as tyrosine kinase inhibitors for patients with Philadelphia-positive CML represents one of the truly breakthrough treatment of cancer that could be helpful to accomplish a stage of MRD or possibly cure certain cancers [66, 67]. Effective anti-angiogenesis may also contribute accomplishing a stage of MRD, yet unlikely to eliminate all existing malignant cells [68]. Ongoing investigations resulting in precision medicine may also eventually lead to effective procedures for selective targeting cancer cells but until then, immunotherapy seems to present treatment of choice for an increasing number of indications.

Perhaps one of the most promising strategies currently used successfully for treatment of cancer using patient’s own killer cells, at present especially effective against malignant B cell disorders, B cell leukemias and non-Hodgkin lymphomas, is the CAR-T technology based on targeting patient’s own activated T cells against malignant cells [69, 70]. Unfortunately, although treatment with CAR-T induces most effective remissions even in patients with multi-drug resistant hematological disorders recurrent disease cannot be consistently eliminated, thus, most centers prefer to follow treatment with CAR-T with allogeneic stem cell transplantation to control residual malignant cells. Furthermore, CAR-T treatment is frequently accompanied by hazardous cytokine release syndrome. Production of CAR-T is most expensive, time consuming, complicated and involves the use of genetic manipulation of expanded T cells obtained from the patient processed in specially designed GMP facilities. It seems reasonable to predict that future procedures based on CAR-T technology will also focus on the use of allogeneic or even off-the-shelf readily available donor T and NK cells.

Oncolytic viruses are also most promising future agents to eradicate malignant cells resistant to available anti-cancer modalities, either due to direct cytolytic effects of oncolytic viruses and/or due to induction of effective anti-cancer immunity against “modified self”, cancer cells “decorating” and modifying cancer cells with viral antigens [71]. As such, the use of cancer targeting oncolytic viruses may represent a method for combining direct anti-cancer cytolysis with induction of anti-cancer immunotherapy by breaking T cells-cancer tolerance.

Another interesting future treatment of cancer including elimination of cancer stem cells may involve delivery of anti-cancer molecules such as tumor suppressor microRNAs or oncolytic viruses by MSCs that naturally migrate to and target cancer cells and as such can be used as messengers of anti-cancer agents [72]. As such, neutralizing the immunosuppressive effects of MSCs in the tumor microenvironment may be accomplished by loading MSCs with agents that will use such MSCs as anti-cancer chaperons.

Discussion

Immunotherapy is now recognized as one of the most promising approaches for control, possibly even for eliminate cancer cells resistant to available anti-cancer modalities, including cancer stem cells that are a priori resistant to chemotherapy and radiation therapy. Most if not all available immunotherapy procedures are based on an attempt to activate patient’s own immune system against patient’s own malignant cells, either by controlling negative regulators of the immune system including regulatory T cells and using checkpoint inhibitors on the one hand, or activation of anti-cancer effector mechanisms by cytokines, using monoclonal antibodies that can induce antibody-dependent cell-mediated cytotoxicity or targeting larger number of spontaneously generated tumor-reactive T cells, tumor-infiltrating lymphocytes (TIL) or the most recent advanced targeting of patient’s own T cells against cancer-associated antigens by chimeric antigen receptor T cells (CAR-T), on the other. Yet, cure of patients with advanced and resistant malignant disease is rarely accomplished.

As suggested by this paper, optimal treatment of cancer aiming for cure, should focus on two principles: first, focusing on an attempt to eliminate MRD at an early stage of the disease which can be accomplished in the large majority of patients with cancer following successful conventional treatment; second, application of optimal anti-cancer immunotherapy at the stage of MRD. As documented by pre-clinical animal experiments [5, 15, 18, 21, 22, 73] and our successful pilot clinical investigations [25, 41, 47, 48, 50], ATACK represents a safe method for elimination of fully resistant residual malignant cells.

The first approach consists of the conventional standard of care, based on fully personalized treatment that now should also include precision medicine and additional relevant procedures such as hormonal treatment, immunotherapy by monoclonal antibodies, kinase inhibitors etc., as indicated. As suggested by our current working hypothesis supported by most encouraging pilot clinical investigations, the second approach, preferably applicable at the stage of MRD against otherwise persistent malignant cells, may result in cure because of the capacity of IL-2 activated killer cells to kill any mismatched target cells including cancer cells resistant to chemotherapy including cancer stem cell. Ideally, the common practice of experts of infectious diseases that always recommend aggressive treatment of bacterial infections, should also be applied by oncologists and hematologists for treatment of cancer, as long as eradication of MRD could be accomplished by a safe immunotherapy program, such as the one recommended here with. As such, the goal should be to recognize the high-risk cases upfront and treat MRD by immunotherapy, even if residual malignant cells cannot be visible, since cancer micro-metastases of one million cells or less are never visible and invisible cancer stem cells are a priori resistant to chemotherapy and ionizing radiation. In sharp contrast, no cure can be anticipated by treatment of patients with a heavy tumor load, late in the course of the disease, when uncontrolled metastases are already visible in patients with poor performance status, after failure of multiple courses of ineffective chemotherapy.

The “take home” message seems to be that at the stage of minimal residual disease targeted anti-cancer modalities focusing on innovative immunotherapy may provide the optimal stage for successful treatment and possibly the only chance to cure the
disease. Indeed, the goal should remain to cure cancer which probably can be accomplished by smart immunotherapy such as ATACK when applied at the stage of MRD, as confirmed in pre-clinical animal models [5, 15, 18, 21, 22, 73] and by cumulative successful clinical experience [25, 41, 47, 48, 50], rather than regarding cancer as an incurable chronic disease that needs to be treated only when the patient is symptomatic or with obvious evidence of disease. Taken together, the feasibility to eradicate otherwise resistant malignant cells at the stage of MRD should serve as a reminder to consider immunotherapy at the stage of MRD even in asymptomatic patients with high-risk disease. Based on our most encouraging preliminary experience, our working hypothesis should be further investigated in prospective randomized clinical trials by combining optimal conventional anti-cancer modalities and ATACK mediated by short-term circulation of most potent non-engrafting killer cells, best starting in patients with hematological malignancies, focusing on acute leukemia and multiple myeloma.

**Abbreviations**

MRD: minimal residual disease; ATACK, Allogeneic Targeted Activated Cancer Killer cells: NK cells, natural killer cells: SCT: stem cell transplantation, DLI, donor lymphocyte infusion; GVHD: graft-vs-host disease; GVL: graft-versus-leukemia effects, GVT, graft-vs-tumor effects: NST: non-myeloablative stem cell transplantation: RIC: reduced intensity conditioning

**Acknowledgements**

I wish to thank my former medical team at the Hadassah Medical Center and the scientists at the Baxter-Hadassah Research laboratory in Jerusalem, particularly Prof. Reuven Or, Prof. Ella Naparstek and Prof. Arnon Nagler for many years of fruitful collaboration while I was chairing Israel’s National Center for Stem Cell Transplantation & Cancer Immunotherapy.

**Declaration**

Prof. Slavin is currently involved in treatment of patients with cancer focusing on immunotherapy in his private clinic in Tel Aviv.

**References**

1. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol. 1983;1:517-31.
2. Grathwohl A, Hermans J, Goldman JM, et al. Chronic Leukemia Working Party of the EBMT, Chronic leukemia. Lancet. 1998;352:1087.
3. Passweg JR, Rowlings PA, Armitage JO, et al. Report from the international bone marrow transplant registry and autologous blood and marrow /transplant registry, North America. Clin transpl. 1995:117-27.
4. Bast CR. Principles of cancer biology: tumour immunology. In: DeVitta VT, Hellman S, Rosenberg SA, Editors. Cancer: principles & practice of oncology. Philadelphia: J.B. Lippincott Company.1985:125-41.
5. Weiss L, Lubin I, Factorowich Y, et al. Effective graft vs leukemia effects independent of graft vs host disease after T-Cell depleted allogeneic bone marrow transplantation in a murine model of B Cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol. 1994;153(6):2562-7.
6. Grillo-Lopez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1-9 (Review).
7. Thomas ED. The role of bone marrow transplantation in the eradication of malignant disease. Cancer 1963;49:1963-8.
8. Weiden PL, Sullivan KM, Flormoy N, et al. Anti-leukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med. 1981;304:1529-33.
9. Weiden PL, Flormoy N, Sanders JE, et al. Anti-leukemic effect of graft-versus-host disease contributes to /improved survival after allogeneic marrow transplantation. Transplantation. 1981;13:248-51.
10. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720-6.
11. Horowitz M, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-62.
12. Sinkovics JG, Shullenberger CC, Howe CD, et al. Prolongation and prevention of Rauscher virus mouse leukemia by spleen cells of naturally resistant or actively immunized mice. Clin Res. 1965;13:36-9.
13. Boranic M, Tonkovic I. Time pattern of the anti-leukemia effect of graft-versus-host reaction in mice. I. Cellular events. Cancer Res. 1992;31:1140-7.
14. Bortin MM, Truitt RL, Rimm AA, et al. Graft-versus-leukemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature. 1979;281:490-1.
15. Slavin S, Weiss L, Morecki S, et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother. 1981;11:155-61.
16. Truitt RL, Shih F-H, LeFever AV, et al. Characterization of alloimmunization-induced Tlymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol. 1983;131:2050-8.
17. Meredith RF, O’Kunewick JP. Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation. Transplantation. 1983;35:378-85.
18. Weiss L, Weigensberg M, Morecki S, et al. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol Immunother. 1990;31:236-42.
19. Truitt RL, Atasoylu AA. Impact of pre-transplant conditioning/and donor T cells on chimerism, graft-versus-host disease, graft-vs-leukemia reactivity, and tolerance after bone marrow transplantation. Blood. 1991;77:2515-23.
20. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB-NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997-1000.
21. Morecki S, Moshef Y, Gelfand Y, et al. Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer. 1997;71:59-63.
22. Morecki S, Yacovlev E, Diab A, et al. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 1998;58:3891-5.
23. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a
24. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986-93.

25. Or R, Ackerstein A, Nagler A, et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study, Cytokines, Cellular & Molecular Therapy. 1998;4:1-6.

26. Higano CS, Brixey M, Bryant EM, et al. Durable complete remission of acute non-lymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transfusion. 1990;50:175-8.

27. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77(7):1423-8.

28. Weiss L, Reich S, Slavin S, et al. Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990;6:229-33.

29. Kapelushnik J, Or R, Aker M, et al. Allogeneic cell therapy of severe beta-thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant. 1996;19:96-8.

30. Kapelushnik J, Aker M, Or R, et al. Allogeneic cell therapy as a new modality for displacement of genetically abnormal stem cells as part of the conditioning for allogeneic bone marrow transplantation. Correction of genetic diseases by transplantation (Chapter 4). Cogent Press.1997:111-9.

31. Aker M, Kapelushnik J, Pugatsch T, et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT for beta-thalassemia major. J Pediatr Hematol Oncol. 1998;20(2):145-8.

32. Slavin S, Nagler A, Naparstek E, et al. Mini-transplants and cell based therapies for malignant and non-malignant disorders. Curr Opin Organ Transplant. 1999;4(3):184-8.

33. Slavin S, Or R, Naparstek E, et al. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood. 1988;22(suppl 1):407a.

34. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553-62.

35. Slavin S, Nagar A, Naparstek E, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood.1996;87:35-204.

36. Kolb HJ, Mittermuller J, Clemm C, et al. Donor lymphocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood.1990;76:2462-5.

37. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for blood and marrow transplantation. Blood.1995;86:2041-50.

38. Collins RH, Shpilberg O, Drohyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol.1997;15:433-44.

39. Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med.1994;330:100-6.

40. Mackinnon S, Papadopoulos EB, Carabassi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood.1995;86:1261-8.

41. Slavin S, Morecki S, Weiss L, Or R, et al. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Critical Reviews in Hematology/Oncology.2003;46(2):139-163.

42. Naparstek E, Or R, Nagler A, et al. cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Brit J Haematol.1995;89:506-515.

43. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-vs-leukemia without myeloablative therapy. Blood.1997;89(12);4531-4536.

44. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytodestruction for the treatment of malignant and non malignant hematologic diseases. Blood.1998;91(3):756-763.

45. Childs R, Chenhoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med.2000;343(11):750-8.

46. SlavinS. Cancer immunotherapy with allogeneic lymphocytes. New Engl J Med.2000;343(11):802-803.

47. Slavin S. Immunotherapy of cancer with allogeneic lymphocytes. Lancet Oncology.2001;2:491-8.

48. Slavin S. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation. Acta Haematologica.2005;114:214-220.

49. Or R, Ackerstein A, Nagler A, et al. Allogeneic cell-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after stem cell transplantation. J Immunother. 1998;21(6):447-53.

50. Slavin S, Ackerstein A, Or R, et al. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. Cancer Immunol Immunother.2010 Oct;59(10):1511-9.

51. Morecki S, Lindhofer H, Yacovlev E, et al. Use of triffuncional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood. 2006;107:1564-1569.

52. Morecki S, Lindhofer H, Yacovlev E, et al. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and bifunctional bispecific antibody. Exp Hematol.2008;36(8):997-1003.

53. Weiss L, Reich S, Slavin S, et al. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a
model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest.1992;10:19-26.

55. Eckerstein A, Slavin S, Weiss L, et al. Immunotherapy in conjunction with autologous bone marrow transplantation. Bone Marrow Transplant.1990;5(1):38

56. Nagler A, Ackerstein A, Or R, et al. Immunotherapy with recombinant human interleukin-2 (rIL-2) and recombinant interferon in lymphoma patients post autologous marrow or stem cell transplantation. Blood.1997;89(11):3951-3959.

57. Slavin S, Nagler A. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Annals of Oncology.1998;Suppl 1 (9):S31-S39.

58. Nagler A, Berger R, Ackerstein A, et al. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma post autologous stem cell transplantation. J Immunother.2010;33(3):326-33.

59. Müller E, Speth M, Christopoulos PF, et al. Both Type I and Type II interferons can activate antitumor M1 macrophages when combined with TLR stimulation. Front Immunol.2018;9:2520.

60. Pozzi LM, Maciaszek JW, Rock KJ, et al. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol.2005, 175 (4):2071-2081.

61. Aznar MA, Tinari N, Rullán AJ, et al. Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally. J Immunol.2017;198:31-39.

62. Tanaka A, Sakaguchi S. et al. Regulatory T cells in cancer immunotherapy. Cell Res.2017;27(1):109-118.

63. Tang F, Du X, Liu M, et al. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade? Cell Biosci.2018;8:30.

64. Judith A. Seidel, Atsushi Otsuka, et al. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018; 8: 86.

65. Liu Y, Wei G, Cheng WA, et al., Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunol Immunoother.2018;67(8):1181-1195.

66. Kamdje AHN, Kamga PT, Simo RT, et al., Mesenchymal stromal cells’ role in tumor microenvironment: involvement of signaling pathways. Cancer Biol Med.2017;14(2): 129-141.

67. Druk R, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med.2001;344(14):1031-7.

68. Carmi C, Mor M, Petronini PG, et al. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol.2012;84(11):1388-99. Review.

69. Young RJ, Reed MW. Anti-angiogenic therapy: concept to clinic. Microcirculation. 2012;19(2):115-25. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 168 (4): 724-740.

70. Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. The New Eng J Med.2018, 8(8):958-971.

71. Ferguson MS, Lemoine NR, Wang Y. Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles. Adv Virol. 2012, 2012: Article ID 805629, 14 pages.

72. Lee HK, Finniss S, Cazacu S, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4(2):346-61.

73. Cohen P, Vourka-Karussis U, Weiss L, et al. Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol. 1993;151:4803-4810.

To cite this article: Slavin S. Towards Possible Cure of Cancer by Immunotherapy of Minimal Residual Disease Using Intentionally Mismatched Donor Lymphocytes. British Journal of Cancer Research. 2020: 3:2.

© Slavin S. 2020.